• Prevention of venous thrombosis and embolism during surgical interventions in patients at moderate and high risk, especially orthopedic and general surgical
• interventions, including oncological
• Prevention of venous thrombosis and embolism in patients on bed rest due to acute therapeutic diseases, including acute heart failure and decompensation of chronic heart failure (NYHA class III or IV), respiratory failure, as well as severe infections and rheumatic diseases with an increased risk of venous thrombosis (see section "Special instructions")
• Treatment of deep vein thrombosis with or without pulmonary embolism, except in cases of pulmonary embolism requiring thrombolytic therapy or surgery
• Prevention of thrombosis in the extracorporeal circulation system during hemodialysis
• Acute coronary syndrome: - treatment of unstable angina and non-ST segment elevation myocardial infarction in combination with oral administration of acetylsalicylic acid; - treatment of acute ST-segment elevation myocardial infarction in patients undergoing drug treatment or subsequent percutaneous coronary intervention (PCI)

Accidental overdose of ENOPARIN® with intravenous, extracorporeal or subcutaneous administration can lead to hemorrhagic complications. When ingested, even in large doses, absorption of the drug is unlikely.

For more information about all possible adverse reactions and the frequency of their occurrence, see the instructions in the leaflet.

• Hypersensitivity to sodium enoxaparin, heparin or its derivatives, including other low molecular weight heparins
• Active clinically significant bleeding, as well as conditions and diseases in which there is a high risk of bleeding, including a recent hemorrhagic stroke, acute ulceration of the gastrointestinal tract (GIT), the presence of a malignant neoplasm with a high risk of bleeding, recent operations on the brain and spinal cord, ophthalmic surgery, known or suspected presence of varicose veins esophageal vein dilation, arteriovenous malformations, vascular aneurysms, vascular abnormalities of the spinal cord and brain
• Spinal or epidural anesthesia or loco-regional anesthesia, when sodium enoxaparin was used for treatment in the previous 24 hours
• Immuno—mediated - heparin-induced — thrombocytopenia (in the anamnesis) for the last 100 days or the presence of circulating antiplatelet antibodies in the blood
• Children under 18 years of age, as efficacy and safety in this category of patients have not been established (see section "Special instructions")

The drug ENOPARIN® should not be mixed with other drugs!
No recommended combinations
Drugs that affect hemostasis (systemic salicylates, acetylsalicylic acid in doses that have an anti-inflammatory effect, nonsteroidal anti-inflammatory drugs (NSAIDs), including ketorolac, other thrombolytics (alteplase, reteplase, streptokinase, tenecteplase, urokinase)), it is recommended to cancel before starting therapy with sodium enoxaparin. If necessary, simultaneous use with enoxaparin sodium should be used with caution and careful clinical observation and monitoring of appropriate laboratory parameters should be carried out.

Registration certificate holder
JSC Biochemist, Russian Federation
15A Vasenko St., Saransk, Republic of Mordovia, 430030
Manufacturer
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, 430030, Republic of Mordovia
Phone number: +7 (8342) 38 03 68
Email: biohimic@promomed.pro
Internet address: promomed.ru
An organization that accepts consumer claims
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, 430030, Republic of Mordovia
Phone number: 8 800 222 95 63; 8 800 777 86 04 ( around the clock)
Email: hot_line@promomed.pro

At a temperature not exceeding 25 ° C. Do not freeze. Keep out of reach of children.

3 years. Do not apply after the expiration date indicated on the package.

Available by prescription